PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Update

PDS Biotechnology's short interest rose 172.7% in the first half of September to 6.41 million shares, from 2.35 million shares at August 31. Despite the sharp increase in bearish positioning, average daily trading volume of 97.84 million shares implies very low days-to-cover, limiting the immediate risk of a sustained short-squeeze dynamic.

Analysis

The relevant signal is not the headline short-interest increase but the implied liquidity profile: if the reported volume figure is accurate, the short position can be recycled or covered in well under one trading day. That makes a mechanical short squeeze unlikely and suggests the positioning may reflect hedged biotech-arbitrage activity, stale volume data, or directional skepticism ahead of a company-specific clinical, financing, or regulatory catalyst rather than a durable borrow constraint. Verify exchange-reported volume and securities-lending utilization before assigning any squeeze probability.

For a pre-revenue biotech, rising bearish positioning raises the cost of a negative catalyst: any delay, weak efficacy/safety update, or capital raise can produce a rapid air-pocket as shorts press into limited natural institutional demand. Conversely, a credible positive data or regulatory event could still drive a multi-day gap because biotech shorts often cover into uncertainty, but that is a fundamental binary rather than a flow-driven setup. Over the next 1-3 months, cash runway, ATM usage, and the timing of material clinical disclosures matter more than short-interest changes; a financing announcement or guidance revision would falsify a bullish interpretation of the setup.

Key Decisions for Investors

• No standalone long based on short interest: require confirmation that days-to-cover exceeds 3x and borrow utilization/rebate rates are tightening before considering a squeeze trade.
• For portfolios with biotech exposure, treat PDSB as a high-volatility event-risk name and avoid unhedged positions into the next material clinical or regulatory update unless the cash runway is independently verified.
• If independently verified clinical data are due within 30-60 days, consider a defined-risk long straddle/strangle only after implied volatility is compared with prior event moves; avoid if implied move already exceeds the stock's historical post-event range.
• A tactical short is only attractive after a failed catalyst bounce or a disclosed dilutive financing: use a hard stop above the event-day high, as positive data can produce discontinuous upside that is not constrained by the reported short-interest ratio.